Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00126620 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
17
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University Health Network, Toronto

Collaborators